On Monday, India’s antitrust regulator approved swapping of the animal health and consumer healthcare businesses between French drugmaker Sanofi and Germany-based Boehringer Ingelheim GmbH (BI) in a deal worth $25 billion.
With the asset swap, Sanofi is set to become the global leader in the sale of over-the-counter medicines, with 4.6% of the world’s consumer healthcare market.
The approval by the Competition Commission of India (CCI) is part of the local regulatory clearances required for the global asset swap between the two companies announced in June. Sanofi is set to acquire BI’s non-prescription drugs business (except for in mainland China) and BI will take over the French company’s animal health unit Merial.
Full Content: Live Mint
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Biden Administration Supports Antitrust Suit Against FIFA
Mar 18, 2024 by
CPI
Apple in Talks to Incorporate Google’s Gemini AI Amid Antitrust Scrutiny
Mar 18, 2024 by
CPI
Appeals Court Revives Regeneron’s Antitrust Lawsuit Against Novartis Over Vision Treatment
Mar 18, 2024 by
CPI
Apple Responds to Criticism Over EU’s Digital Markets Act Compliance
Mar 18, 2024 by
CPI
Turkey Imposes Interim Measures on Meta Platforms
Mar 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pricing Algorithms
Feb 28, 2024 by
CPI
Pricing Algorithms and Antitrust Enforcement: Sandboxes to the Rescue?
Feb 28, 2024 by
CPI
AI, Algorithmic Pricing, and Collusion
Feb 28, 2024 by
CPI
Competition & Collusion in a World of Algorithmic Pricing: Antitrust Risks & Enforcement Trends
Feb 28, 2024 by
CPI
Pricing Algorithms in Antitrust’s Sights?
Feb 28, 2024 by
CPI